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Background: High expression of Bmi-1, a key regulatory component of the polycomb repressive complex-1, has
been associated with many solid and hematologic malignancies including esophageal squamous cell carcinoma.
However, little is known about the role of Bmi-1 in esophageal adenocarcinoma. The aim of this study is to
investigate the amplification and high expression of Bmi-1 and the associated clinicopathologic characteristics in
esophageal adenocarcinoma and squamous cell carcinoma.
Methods: The protein expression level of Bmi-1 was detected by immunohistochemistry (IHC) from tissue
microarrays (TMA) constructed at the University of Rochester from using tissues accrued between 1997 and 2005.
Types of tissues included adenocarcinoma, squamous cell carcinoma and precancerous lesions. Patients’ survival
data, demographics, histologic diagnoses and tumor staging data were collected. The intensity (0–3) and
percentage of Bmi-1 expression on TMA slides were scored by two pathologists. Genomic DNA from 116
esophageal adenocarcinoma was analyzed for copy number aberrations using Affymetrix SNP 6.0 arrays. Fisher
exact tests and Kaplan-Meier methods were used to analyze data.
Results: By IHC, Bmi-1 was focally expressed in the basal layers of almost all esophageal squamous mucosa, which
was similar to previous reports in other organs related to stem cells. High Bmi-1 expression significantly increased
from squamous epithelium (7%), columnar cell metaplasia (22%), Barrett’s esophagus (22%), to low- (45%) and
high-grade dysplasia (43%) and adenocarcinoma (37%). The expression level of Bmi-1 was significantly associated
with esophageal adenocarcinoma differentiation. In esophageal adenocarcinoma, Bmi-1 amplification was detected
by DNA microarray in a low percentage (3%). However, high Bmi-1 expression did not show an association with
overall survival in both esophageal adenocarcinoma and squamous cell carcinoma.
Conclusions: This study demonstrates that high expression Bmi-1 is associated with esophageal adenocarcinoma
and precancerous lesions, which implies that Bmi-1 plays an important role in early carcinogenesis in esophageal
adenocarcinoma.
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Esophageal carcinoma is the 8th leading cancer in inci-
dence and 6th in mortality worldwide, but it is one of the
least studied cancers [1,2]. Squamous cell carcinoma and
adenocarcinoma are the two histologic types that make
up for greater than 90 percent of the diagnoses of
esophageal cancers [3]. Worldwide, the majority of
esophageal cancers are squamous cell carcinoma [2].
However, in the United States and Western countries,
there has been a dramatic rise in the incidence of esopha-
geal adenocarcinoma to equal or exceed the incidence of
esophageal squamous cell carcinoma [4]. Esophageal car-
cinoma carries a poor prognosis with an overall five-year
survival rate of approximately 15 percent in the United
States [5]. More than 50 percent of patients have either
unresectable tumors or radiographically visible metasta-
ses at the time of diagnosis [6]. Identification of early
diagnostic markers with high sensitivity and specificity
will provide physicians with valuable information for
diagnosis, prognosis, and possible treatment options of
esophageal carcinoma. Previous studies have suggested
the order of events that leads to esophageal adenocarcin-
oma from normal esophageal epithelium to reflux
esophagitis, followed by Barrett’s esophagus, dysplasia, to
esophageal adenocarcinoma [7]. During these events, a
series of genetic and epigenetic aberrations driven by
inflammation and oxidative stress contributes to the
carcinogenesis. However, the oncogenetic mechanisms
of esophageal adenocarcinoma remain unclear.
The Bmi-1 (B cell-specific Moloney murine leukemia
virus integration site 1) gene, a member of the
polycomb-group proteins, was first isolated as an onco-
gene that cooperates with c-myc in the oncogenesis of
murine lymphomas [8-10]. It functions as a transcrip-
tional repressor through chromatin modification and
plays a role in axial patterning, cell cycle regulation,
hematopoiesis, and senescence [11,12]. In addition, de-
regulation of polycomb-group gene expression leads to
cell proliferation and tumor progression [13,14]. Aber-
rant Bmi-1 expression has been associated with many
solid and hematologic malignancies, including mantle
cell lymphoma [15], Hodgkin lymphoma [16], B-cell
non-Hodgkin lymphoma [17], gastric carcinoma [18],
hepatocellular carcinoma [19], colorectal cancer [20,21],
breast cancer [22,23], bladder cancer [24], nasopharyn-
geal carcinoma [25], oral squamous cell carcinoma [26]
and non-small cell lung cancer [27]. More recently, stud-
ies have reported an association between Bmi-1 expres-
sion and esophageal squamous cell carcinoma [28-30].
However, little is known about the role of Bmi-1 in
esophageal adenocarcinoma.
The aims of this study are (1) to investigate the associ-
ation of high Bmi-1 expression with the oncogenic pro-
gression of esophageal adenocarcinoma from squamousmucosa, columnar cell metaplasia, Barrett’s esophagus,
low- and high-grade dysplasia to adenocarcinoma, and
(2) to determine the relationship of high Bmi-1 expres-
sion with clinicopathologic characteristics including gen-
der, age, differentiation, and tumor stage in both
esophageal adenocarcinoma and squamous cell
carcinoma.
Methods
Construction of Tissue Microarray
Tissue microarrays, containing 80 cases of squamous epi-
thelium, 63 cases of columnar cell metaplasia, 36 cases of
Barrett’s esophagus, 20 cases of low-grade dysplasia, 14
cases of high-grade dysplasia, 110 cases of esophageal
adenocarcinoma, and 34 cases of esophageal squamous
cell carcinoma, were constructed from representative
areas of formalin-fixed specimens collected from 1997 to
2005 in the Department of Pathology and Laboratory
Medicine, University of Rochester Medical Center/Strong
Memorial Hospital, Rochester, NY. All research was per-
formed under protocols approved at URMC with the title
“Biomarkers of esophageal carcinoma” and RSRB case
number: RSRB00028546. The 5-μm sections were cut
from tissue microarrays and stained with H&E to confirm
the presence of the expected tissue histology within each
tissue core. Additional sections were cut for immunohisto-
chemistry analysis.
Pathologic definition of esophageal adenocarcinoma and
precancerous lesions
Columnar cell metaplasia was defined as columnar cells
without goblet cell metaplasia including mucous glands
or mixture of mucous and oxyntic glands. Barrett’s
esophagus was defined as mucous glands with goblet cell
metaplasia. Low-grade dysplasia was defined as elongated,
crowded, hyperchromatic, mucin depletion and pseudo-
stratified nuclei with relatively preserved crypt architec-
ture. High-grade dysplasia was defined as marked cytolo-
gic abnormality and significant architectural complexity
of the glands. Cytologic abnormalities included nuclear
pleomorphism, loss of polarity, irregularity of nuclear
contour, increased ratio, and increased number of atypical
mitoses. Significant architectural complexities of the
glands included crypt budding, branching, marked crowd-
ing or villiform contour, intraluminal papillae, bridges or
a cribriform growth pattern. Esophageal adenocarcinoma
was defined as the single cells, small or large irregular
glands with both cytologic abnormality and architectural
complexity infiltrating into submucosa or deeper layers of
esophagus.
Patients for Tissue Microarrays
All the 110 patients with esophageal adenocarcinoma used
for the tissue microarray construction were treated with
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ter/Strong Memorial Hospital from 1997 to 2005 without
pre-operation neoadjuvant therapy. These patients
included 98 males (89%) and 12 females (11%). The pa-
tient age ranged from 34 to 85 years with a mean of 65
years (Table 1). The stage, lymph node with or without
metastasis, and differentiation information were listed in
Table 2. The follow-up period after esophagectomy ranged
from 0.03 to 142 months with a mean of 39 months.Patients for Affymetrix SNP 6.0 analysis
Frozen tumors were obtained from 116 patients under-
going esophagectomy at the University of Pittsburgh
Medical Center, Pittsburgh, PA between 2002 and 2008.
The patients' ages ranged from 43 to 88 and the cohort
consisted of 95 males and 21 females. The final patho-
logic stages were stage I (28), stage II (31), stage III (49)
and stage IV (7). All tumor specimens were evaluated by
a pathologist and determined to be >70% tumor cell rep-
resentation. Further information on this patient cohort
and a comprehensive genomic analysis of these tumors
were published by Dulak et al. [31]. Microarray data on
this cohort has been submitted to the Gene Expression
Omnibus (GSE36460) and was made public (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36460). A
research was performed under protocols approved at
both participating institutions.Affymetrix SNP 6.0 analysis
Genomic DNA was isolated using the QiaAmp DNA
Mini Kit (Qiagen, CA), and 600ng was used for labeling
and array hybridization at the SUNY Upstate Medical
University microarray core facility (Syracuse, NY) using
kits and protocols provided by Affymetrix. Array data
quality was assessed using Affymetrix Genotyping Con-
sole 3.0 and all further data analysis was performed
using Nexus 5.0 Copy Number Analysis software (Bio-
discovery, Inc. CA).Table 1 Distribution of patients by histologic types
Male
Histologic type n (%) A
Adenocarcinoma 98 (89) 6
High-grade dysplasia 12 (86) 6
Low-grade dysplasia 20 (100) 6
Barrett’s esophagus 32 (89) 6
Columnar cell metaplasia 56 (89) 6
Squamous cell carcinoma 24 (71) 6
Squamous epithelium 63 (79) 6
NA- non-available.Immunohistochemistry
Tissue sections from the tissue microarray were deparaf-
finized, rehydrated through graded alcohols, and washed
with phosphate buffered saline. Antigen retrieval for
Bmi-1 was performed by heating sections in 99°C water
bath for 40 minutes. After endogenous peroxidase activ-
ity was quenched and nonspecific binding was blocked,
ready-to-use mouse monoclonal antibody anti-Bmi-1
(Millipore, MA) was incubated at room temperature for
30 minutes. The secondary antibody (Flex HRP) was
allowed to incubate for 30 minutes. After washing, sec-
tions were incubated with Flex DAB Chromogen for 10
minutes and counterstained with Flex Hematoxylin for 5
minutes. A colon adenocarcinoma with known high
Bmi-1 expression served as positive control. Negative
control was performed by replacing anti-Bmi-1 antibody
with normal serum. A few core samples did not survival
from the immunohistochemical staining.
Scoring of Immunohistochemistry
All sections were reviewed independently by BC and ZZ
blinded to all clinical and pathologic information. Discord-
ant cases were reviewed by both BC and ZZ and a final
consensus was reached. The percentage (0-100%) of the
cells with positive nuclear staining was recorded. The
cytoplasmic staining, identified in some cases, may repre-
sent cross-reaction of anti-body. However, Bmi-1 muta-
tion with KRMK blocks Bmi-1 nuclear translocation,
which may also cause Bmi-1 staining in the cytoplasm
[32]. Therefore, the cytoplasm stain was not counted in
this study. The intensity of Bmi-1 nuclear staining was
graded as 0, 1+, 2+, or 3+ (Figure 1). Bmi-1 protein was
considered highly expressed if 10% or more of cells
stained with a moderate to strong intensity (2+ and 3+,
respectively).
Statistical analysis
All the descriptive statistics in this study were presented
as mean. A P-value of less than 0.05 was considered sta-
tistically significant. The univariate analysis of Bmi-1 wasFemale
ge (mean) n (%) Age (mean)
5 12 (11) 70
5 2 (14) 71
6 0 (0) NA*
6 4 (11) 69
4 7 (11) 66
5 10 (29) 61
4 17 (21) 65
Table 2 Association of high Bmi-1 expression with age, gender, lymph node metastasis, stage and differentiation in
esophageal adenocarcinoma
Bmi-1 Non-high expression Bmi-1 High-expression p value
Age 66 (34–83) 63 (43–85) 0.284
Gender 0.529
Male 60 38
Female 9 3
Lymph node metastasis 0.283
Positive 52 27
Negative 17 14
p Staging 0.412
I 16 12
II 32 18
III 10 5
IV 7 3
Differentiation 0.004
Well 44 19
Moderate 19 15
Poor 2 4
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lysis, including age, gender, and clinical covariate: lymph
node metastasis and tumor stage. We divided esophageal
adenocarcinoma, high- and low- and grade dysplasia, col-
umnar cell metaplasia as group 1, and squamous cellFigure 1 High Bmi-1 expression in various histologic types by immun
basal layer of normal esophageal squamous epithelium; B. Distribution of B
metaplasia; C. Bmi-1 positive cells mostly at the base of glands in intestinal
of low-grade dysplasia glands.carcinoma and squamous epithelium as group 2. Chi-
square and Fisher exact tests were used as appropriate to
compare Bmi-1 positivity rate in the two groups. To
evaluate the influence of amplification and high expres-
sion of Bmi-1 in esophageal adenocarcinoma andohistochemical studies. A. Bmi-1 positive cells predominantly in the
mi-1 positive cells mostly at the base of glands in columnar cell
metaplasia; D. Distribution of Bmi-1 positive cells evenly in the glands
age, gender, stage, and lymph node metastasis.
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the Kaplan-Meier method compared by the log-rank test
was performed with Bmi-1 amplified and non-amplified
groups. All the statistical analyses were conducted with
SAS 9.3 software (SAS Institute Inc., Cary, NC).
Results
Immunohistochemical characteristics and analysis of
Bmi-1 expression
Bmi-1 was expressed in almost all of the esophageal spe-
cimens. The expression of Bmi-1 in normal squamous
epithelium was mostly located in the basal layers, which
is similar to the previous reports in other organs related
to stem cells (Figure 1) [33,34]. The expression of Bmi-1
in columnar cell metaplasia and Barrett’s esophagus also
distributed at the base of glands, but the intensity and
percentage of Bmi-1 was greatly increased. However, the
expression of Bmi-1 in low- and high-grade dysplasia,
esophageal adenocarcinoma and squamous cell carcin-
oma was evenly distributed throughout the full lesion
(Figures 1, 2 and 3).
High Bmi-1 expression was identified in all histologic
types from squamous epithelium to carcinoma (Figures 1,
2 and 3). However, the percentage of high Bmi-1 expres-
sion increased following the histologic changes from squa-
mous epithelium (7%) to columnar cell metaplasia (22%),
Barrett’s esophagus (22%), low-grade dysplasia (45%),
high-grade dysplasia (43%) and esophageal adenocarcin-
oma (37%) (Table 3). The frequency of high Bmi-1 expres-
sion in Barrett’s esophagus and columnar cell metaplasia
was significantly greater than squamous epitheliumFigure 2 Immunohistochemical score of Bmi-1 in esophageal adenoca
Bmi-1 weakly positive cells distributed evenly in EAC glands (score 1+); C. B
2+); D. Bmi-1 strongly postive cells are distributed in mostly at the base of(p < 0.05). The esophageal adenocarcinoma and low- and
high-grade dysplasia groups, also showed significantly
greater frequency of high Bmi-1 expression compared
with the Barrett’s esophagus and columnar cell metaplasia
groups (p < 0.05). However, there was no significant differ-
ence between esophageal adenocarcinoma, low- and high-
grade dysplasia.
Nine of 34 cases of esophageal squamous cell carcin-
oma and 6 of 80 cases of squamous epithelium showed
high expression of Bmi-1 (Figure 3, Table 3). The
esophageal squamous cell carcinoma group showed sig-
nificantly high Bmi-1 expression compared with the
squamous epithelium group (p = 0.008).Correlation of high Bmi-1 expression and
clinicopathologic characteristics
The correlation of high Bmi-1 expression with clinico-
pathologic features was analyzed. High expression of
Bmi-1 was significantly associated with poor differenti-
ation in esophageal adenocarcinoma (67%) (Table 2).
However, Bmi-1 expression was not associated withSurvival analysis
Kaplan-Meier analysis compared by the log-rank test was
used to calculate the effect of the high Bmi-1 expression
in patients with esophageal adenocarcinoma and squa-
mous cell carcinoma on overall survival. For esophageal
adenocarcinoma, the overall survival in the group with
high Bmi-1 expression was 38.3 months, while the grouprcinoma (EAC). A. No Bmi-1 expression in EAC glands (score 0); B.
mi-1 moderately positive cells distributed evenly in EAC glands (score
EAC glands (score 3+).
Figure 3 Immunohistochemical score of Bmi-1 in esophageal squamous cell carcinoma (ESCC). A. No Bmi-1 expression in ESCC (score 0);
B. Bmi-1 weakly positive cells distributed evenly in ESCC (score 1+); C. Bmi-1 moderately positive cells distributed evenly in ESCC (score 2+); D.
Bmi-1 strongly positive cells in ESCC (score 3+).
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log-rank test showed a trend towards better overall
survival in the high-Bmi-1 group, but it did not reach stat-
istical significance (p = 0.13, Figure 4A).Genomic analysis of Bmi-1 expression
Analysis of 116 esophageal adenocarcinoma specimens
using high density copy number microarrays revealed
amplification of 3% (4/116) (Figure 5). In this cohort, the
median overall survival of patients with Bmi-1 amplifica-
tion was approximately 10 months and patients with no
Bmi-1 amplification was 25 months. SignificantTable 3 Comparing the percentage of high Bmi-1
expression in various histologic types
Histologic type n Non-high
expression (%)
High
expression (%)
Adenocarcinoma 110 69 (63) 41 (37)
High-grade dysplasia 14 8 (57) 6 (43)
Low-grade dysplasia 20 11 (55) 9 (45)
Barrett’s esophagus 36 28 (78) 8 (22)
Columnar cell metaplasia 63 49 (78) 14 (22)
Squamous cell carcinoma 34 25 (74) 9 (26)
Squamous epithelium 80 74 (93) 6 (7)association of overall survival was found with Bmi-1
amplification (p<0.05).
Discussion
In this study, we reported the first evidence that high
expression of Bmi-1 occurred in esophageal adenocarcin-
oma and its precursor lesions including, low- and high-
grade dysplasia, Barrett’s esophagus and columnar cell
metaplasia. High Bmi-1 expression increased in intensity
and percentage following the early progress of adenocar-
cinoma from squamous epithelium (7%), columnar cell
metaplasia (22%), Barrett’s esophagus (22%), low- (45%)
and high-grade dysplasia (43%) and adenocarcinoma
(37%). The increase in high Bmi-1 expression was signifi-
cant from squamous mucosa to columnar cell metaplasia
and Barrett’s esophagus and from Barrett’s esophagus to
low-grade dysplasia and esophageal adenocarcinoma. In
addition, the expression level of Bmi-1 protein was signifi-
cantly associated with worse histologic grade of esophageal
adenocarcinoma. However, high Bmi-1 expression did not
show an association with overall survival in both esophageal
adenocarcinoma and squamous cell carcinoma. DNA
microarray analysis detected a low percentage of Bmi-1
amplification in esophageal adenocarciinoma..
The carcinogenesis of esophageal adenocarcinoma
from normal epithelium was suggested to involve a series
of events that includes the reflux of gastric and duodenal
Figure 4 Kaplan-Meier analysis of overall survival associated with high Bmi-1 expression and in esophageal adenocarcinoma (A) and
squamous cell carcinoma (B). A. Bmi-1 expression in EAC showed a better but not significant overall survival (p=0.13). B. Bmi-1 expression in
ESCC showed no change. Solid line: non-high expression; Dotted line: high expression.
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followed by Barrett’s esophagus, dysplasia, and esopha-
geal adenocarcinoma [7]. During these events, the accu-
mulation of genetic and epigenetic aberrations driven by
inflammation, as well as acid and bile salt stimulation,Figure 5 Frequency histogram showing amplification of the Bmi-1 loc
samples. This locus was amplified in 4/116 (3%) cases of this patient cohocontributes to the carcinogenesis. A number of genes in-
cluding apoptosis-related genes, cell cycle-related genes,
tumor suppressor genes, oncogenes and growth factors,
have been reported to be involved in esophageal carcino-
genesis. Bmi-1 has a role in epigenetic modification as aus at chromosome 10p12 in 116 esophageal adenocarcinoma
rt (darker green).
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expression may contribute to carcinogenesis [35]. We
found Bmi-1 present in the basal layers of normal squa-
mous mucosa layer where the stem cells are usually
located, but the percentage of expression was very low
and the intensity was weak. However, the percentage and
intensity of high Bmi-1 expression were significantly
increased following the progression from columnar cell
metaplasia to adenocarcinoma. The percentage of high
expression cells were doubled in low- and high-grade
dysplasia compared with to columnar cell metaplasia and
Barrett’s esophagus. Also, the distribution of cells with
high Bmi-1 expression was observed to have a different
pattern, mostly within the base of columnar cells meta-
plasia compared with the full gland distribution in dys-
plasia and adenocarcinoma. The trend of high Bmi-1
expression suggests that Bmi-1 may play an important
role in the early carcinogenesis.
From a previous study, Bmi-1 was reported to act as a
stable transcriptional repressor that regulates inhibitors
of p16INK4a and p19ARF [12]. Our DNA microarray
studies lends support to a previous report that p16 and
p53 play important roles in early carcinogenesis of
esophageal adenocarcinoma [36]. The high expression of
Bmi-1 in precancerous lesion implies that Bmi-1 might
promote cell proliferation by suppressing p16/Rb and/or
p19ARF/MDM2/p53 tumor suppressor pathway in early
carcinogenesis. Therefore, further investigation is needed
for the role of Bmi-1 in relation to p16, p53, and other
signal pathways.
In esophageal adenocarcinoma, the amplification of
Bmi-1 was very low (3%) by DNA microarray study
compared with to the high expression (37%) by immu-
nohistochemical study. From previous studies on gastric
and colonic adenocarcinoma, Bmi-1 was found to upre-
gulate both at the transcriptional and translational levels
[18,20,21]. We assumed that high Bmi-1 expression may
be involved at the transcriptional level without signifi-
cant DNA amplification, suggesting that the higher ex-
pression in esophageal adenocarcinoma is not driven by
changes in the DNA copy number. In addition, the 16p
segment, where Bmi-1 and several genes are located, is
amplified. The worse overall survival may not be solid
evidence to prove the association of Bmi-1 amplification
with prognosis.
We then analyzed the association between Bmi-1 ex-
pression and clinical characteristics of the patients. The
analysis revealed a significant correlation between high
expression of Bmi-1 in esophageal adenocarcinoma with
moderately to poorly differentiated esophageal adenocar-
cinoma. Unlike previous studies on gastric carcinoma
[18], colonic [20], and esophageal squamous cell carcin-
oma [29], we observed no significant correlation be-
tween high expression of Bmi-1 and esophagealadenocarcinoma and squamous cell carcinoma with
other clinicopathologic features such as age, gender,
stage, metastatic lymph nodes. The difference in the cor-
relation between Bmi-1 and clinicopathologic features
may reflect the tissue and population variance of these
studies. The previous studies were performed in the
Chinese population.
While our study showed high Bmi-1 expression of
shows slightly better but not a significant difference in
prognosis in esophageal adenocarcinoma, most studies
showed that high Bmi-1 expression was associated with
poorer prognosis [18-20,24,25,27]. However, Pietersen
et al. did report a correlation between high expression of
Bmi-1 and better outcome in breast cancer patients 22.
The non-significant prognosis for esophageal adenocar-
cinoma was unexpected since other gastrointestinal car-
cinomas showed worse prognosis with high Bmi-1
expression. The different types of epithelium located
throughout the gastrointestinal system, molecular
mechanisms, and population groups may explain this
discrepancy.
In esophageal squamous cell carcinoma, the data on
the association between Bmi-1 expression and prognosis
are limited and conflicting. Our results for esophageal
squamous cell carcinoma are similar to the results from
Yamada et al. where they found no association in prog-
nosis between high expression of Bmi-1 and squamous
cell carcinoma [30]. In contrast, two other reports found
patients with higher expression of Bmi-1 had lower over-
all survival compared with patients with worse expres-
sion of Bmi-1 [28,29].
Conclusion
In conclusion, Bmi-1 was rarely amplified in esophageal
adenocarcinoma, but highly expressed in esophageal
adenocarcinoma and squamous cell carcinoma. High
expression of Bmi-1 was significantly correlated with the
histologic grade of esophageal adenocarcinoma. The ac-
cumulation of high Bmi-1 expression from columnar cell
metaplasia, Barrett’s esophagus, dysplasia to adenocarcin-
oma implies an important role of Bmi-1 in the early de-
velopment of esophageal adenocarcinoma. It also
suggests that Bmi-1 is a potential target for treatment of
precancerous lesions.
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